A Parhurst teardown. In re BioXcel Therapeutics, Inc., No. 26-11360 (Bankr. D. Del.), before Judge Thomas M. Horan. One 8-K read in full and one docket read entry by entry.

If you are going to object to anything here, you have until 15 September. That is nine days. The omnibus hearing is 28 September at 2:00 PM in Courtroom 7 in Wilmington, and the bidding procedures, the DIP and the sealed retention programme are all on it.

Correction

Our front page put the Teva contingent consideration at up to $67.5m. It is up to $87.5m. The 8-K carries a second tranche of up to $20m in Commercial Milestone payments that we missed. Corrected on the front page and below. No issue of the Daily carried the figure.

Three facts that only mean something together

One. The DIP lenders are the prepetition lenders. Affiliates of Oaktree Capital Management and the Qatar Investment Authority financed the company under a credit agreement dated 19 April 2022, amended as recently as three days before the petition.

Two. The facility is up to $19m of new money against up to $58.25m of roll-up. That is 3.07 to 1 at the caps.

Three. The Strategic Process Committee that oversees any sale "was appointed pursuant to the Prepetition Credit Agreement."

Most readers will skim the third one. It is the whole case. The committee that ran the process exists because the lender's credit agreement required it. The lender then financed the case, and the buyer that committee produced signed on the day of the petition.

None of that is improper, and it may be the only structure that kept the company operating. But it frames every recovery question below, and the filing states it plainly.

The roll-up, and what the docket added

A roll-up converts prepetition debt into postpetition debt. Postpetition DIP debt normally primes almost everything below it.

The 8-K did not say what liens or priority the lenders were asking for. The docket does. Entry 24, filed 28 August, seeks senior postpetition security interests and superpriority administrative expense status under sections 364(c) and 364(d), plus use of cash collateral, adequate protection and modification of the automatic stay.

Section 364(d) is the priming request. Sought, not yet granted.

So up to $58.25m of paper that was exposed to the outcome becomes paper that is not, in exchange for up to $19m of new funding.

Now set that against the buyer.

The stalking horse cash does not clear the DIP.

That comparison is cash against debt, and the missing piece is stated but never sized: Teva also assumes the Liabilities. Nobody outside the estate can turn this into a recovery number until a schedule appears, and anyone who publishes one has guessed.

What can be said without guessing: at the caps, a competing bidder has to clear $77.25m of superpriority before a dollar reaches the estate, against a floor bid of $57.5m in cash plus assumed liabilities and up to $87.5m of milestones that are not cash at closing.

The fee to file the petition was $1,738.

Who is in the room

The docket answers the question the 8-K would not.

Two things to notice.

The CRO was appointed days before the petition and is also the first day declarant at entry 2. The person who swore the case in is the person the Strategic Process Committee hired.

And the banker, Daun Chung of MTS, declared in support of both the DIP and the bidding procedures. The same expert supports the financing and the sale it funds. That is entirely normal, and it is also the single declaration an objector would attack.

What is sealed

The Key Employee Retention and Incentive Programs were filed the day after the petition, under seal at entry 36, with a redacted version at 37 and a motion to seal at 39.

So the amounts going to management are not public, and the objection deadline for them is the same 15 September.

Separately, the Court entered an interim order on 31 August establishing notice and objection procedures for transfers of equity securities and a record date for sell-down procedures on claims. That is a trading order to protect tax attributes. Somebody thinks the NOLs are worth protecting, which is a small signal about how the plan is expected to end.

Your seat

What is still not established

• DIP interest, maturity and milestones. Entry 24 seeks them. The numbers sit in the

exhibit, not the docket text.

• Prepetition amount outstanding. The roll-up converts "a portion". $58.25m is a floor

for the claim, not the claim.

• The size of the assumed Liabilities. The largest hole in the analysis.
• The size of the bid protections.
• The KERP and KEIP amounts. Sealed.
• Whether a creditors' committee has been appointed. Not in the entries we read, which

is not the same as not appointed.

The dates that matter

The call

BioXcel Therapeutics, Inc., No. 26-11360 (Bankr. D. Del.) Teva closes as stalking horse with no qualified overbid. Resolves by 30 November 2026. Confidence: medium.

Basis: at the caps a topping bidder must clear $77.25m of superpriority before reaching the estate, against a floor bid of $57.5m cash plus assumed liabilities. The structure discourages a competing bid more than the asset discourages a buyer.

What would break it: a bidder who values the IGALMI sNDA outcome above Teva's milestone ladder, or a challenge to the roll-up inside the challenge period the final order sets.

Call #2 on our public record, with its reasoning and its failure condition.

Sources, both read in full: Form 8-K, event date 27 August 2026, signed 28 August by Richard Steinhart, CFO, and the Delaware docket, read 6 September 2026.

Every figure above appears in one of those or is arithmetic on figures in them, recorded in editorial/facts/bioxcel.json with the sentence it came from. Every figure the documents do not give is listed as missing rather than estimated.

Parhurst is not investment advice. No price targets. No non-public information.